I. F. Tannock

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

I. F. Tannock, Marcin Gospodarowicz, W Meakin et al. · Journal of Clinical Oncology · 1989 · 409 citations

Pain Therapy, Pain Medicine, Cancer Management +17

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

Janette L. Vardy, Kimberly S. Chiew, Jacqueline Galica et al. · British Journal of Cancer · 2006 · 256 citations · Full text

Translational Medicine, Emetogenic Chemotherapy, Oncology +12

Perception of quality of life by patients, partners and treating physicians

K Wilson, Anthony Dowling, Mohamed Abdolell et al. · Quality of Life Research · 2000 · 255 citations

Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain

D. Scott Ernst, I. F. Tannock, Eric Winquist et al. · Journal of Clinical Oncology · 2003 · 248 citations